VRN Belgium has announced a clinical trial investigation site management agreement with ICON, the global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical devices industries.
ICON has selected VRN to manage sites for two clinical trials due to start next month. The SPIRE-1 and SPIRE-2 studies, which ICON is carrying out on behalf of a major global pharmaceutical sponsor, will be conducted through VRN’s growing clinical trials investigation site network in Belgium.
Head of Network Services Anne-Marie Martin said: “We are delighted to be working with Icon, one of the world’s major CROs, on this important clinical trial. Our extensive network in Belgium enabled us to find the right number of suitable sites for the trials, ensuring that patient recruitment targets are met.”
Although VRN was only approached by ICON for the first time about the study at the end of last year, the company completed extensive site feasibility evaluations quickly and effectively, delivering agreements with 14 sites which will now participate in the trial.